Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...
A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk duct ...
In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.
LAGUNA HILLS, Calif., Jan. 16, 2025 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug ...
October 27, 2009 — Women with low- to intermediate-grade ductal carcinoma in situ (DCIS) with margins 3 mm or wider had an "acceptably low rate" of ipsilateral breast events 5 years after excision ...
December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...
LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback